US20030170184A1 - Treatment of actinomyces naeslundii-related diseases with exogenous lactic bacteria strains - Google Patents

Treatment of actinomyces naeslundii-related diseases with exogenous lactic bacteria strains Download PDF

Info

Publication number
US20030170184A1
US20030170184A1 US10/305,024 US30502402A US2003170184A1 US 20030170184 A1 US20030170184 A1 US 20030170184A1 US 30502402 A US30502402 A US 30502402A US 2003170184 A1 US2003170184 A1 US 2003170184A1
Authority
US
United States
Prior art keywords
lactic bacteria
bacteria strain
cncm
composition
strains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/305,024
Other languages
English (en)
Inventor
Elena-Maria Comelli
Bernhard Guggenheim
Jean-Richard Neeser
Francesca Stingele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Assigned to NESTEC S.A. reassignment NESTEC S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GUGGENHEIM, BERNHARD, NEESER, JEAN-RICHARD, COMELLI, ELENA-MARIA, STINGELE, FRANCESCA
Publication of US20030170184A1 publication Critical patent/US20030170184A1/en
Priority to US10/995,891 priority Critical patent/US7491386B2/en
Assigned to NESTEC S.A. reassignment NESTEC S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GUGGENHEIM, BERNHARD, NEESER, JEAN-RICHARD, COMELLI, ELENA-MARIA, STINGELE, FRANCESCA
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00—Chewing gum
    • A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
    • A23G4/12—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A23G4/123—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1236—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt using Leuconostoc, Pediococcus or Streptococcus sp. other than Streptococcus Thermophilus; Artificial sour buttermilk in general
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1238—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt using specific L. bulgaricus or S. thermophilus microorganisms; using entrapped or encapsulated yoghurt bacteria; Physical or chemical treatment of L. bulgaricus or S. thermophilus cultures; Fermentation only with L. bulgaricus or only with S. thermophilus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K40/00—Shaping or working-up of animal feeding-stuffs
    • A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C2220/00—Biochemical treatment
    • A23C2220/20—Treatment with microorganisms
    • A23C2220/206—Slime forming bacteria; Exopolysaccharide or thickener producing bacteria, ropy cultures, so-called filant strains
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/21—Streptococcus, lactococcus
    • A23V2400/249—Thermophilus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/885—Streptococcus

Definitions

  • the present invention relates to the incorporation in the oral microflora of exogenous lactic bacteria that are able to modulate the colonization of A. naeslundii and to reduce the severity of A. naeslundii -related diseases.
  • the mouth (oral cavity) contains a resident and a non-resident microflora.
  • the first includes microorganisms that are able to establish a more or less permanent residence on the oral surfaces. These bacteria are mainly localised on the tongue, the buccal mucosa and the teeth while the gingiva, lips, cheeks, palate and floor of the mouth only support a very sparse microflora.
  • the dental plaque is a film that forms on the surface of teeth consisting of bacterial cells in a matrix of extracellular polysaccharides and salivary products. Immediately after eruption, the teeth are covered with an amorphous layer of saliva, the acquired enamel pellicle (AEP) that is about 1.3 ⁇ m thick and cannot be removed by normal tooth brushing.
  • AEP acquired enamel pellicle
  • the deposition of bacteria on teeth follows immediately the formation of the AEP and plaque becomes evident in 8-12 hours as a multi-layered structure.
  • the first layer consists of bacteria (earliest colonisers) that attach to teeth mainly via specific adhesin-receptor recognition; it forms a substratum for the second colonisers that adhere one to the other via analogous specific binding or via simple juxtaposition.
  • the natural resident microflora includes microorganisms selected from Streptococcus, Veillonella, Bacteroides and Haemophilus.
  • Streptococci and Actinomyces predominate but a variety of Gram positive and negative cocci and rods can be found.
  • Actinomyces naeslundii genospecies 1 (formerly A. naeslundii ) and 2 (formerly A. viscosus ) are common members of human dental plaque. They are among the strongest plaque forming oral strains, because of their capacity to firmly adhere to the teeth and to coaggregate with many other bacterial species, thus fostering their establishment in the mouth. Moreover, in the elderly, they are commonly isolated at root caries sites, and they are believed to be the major etiological agent of this disease (Bowden, G. H., et al.
  • the transient microflora comprises exogenous bacteria that can be occasionally present in the mouth, but that do not establish a permanent residence (even if repeated oral administrations of these bacteria are carried out). All the food bacteria, and in particular lactic acid bacteria, can be part of this transient microflora.
  • lactic bacteria strains that are not part of the resident microflora of the mouth, that are low acidifying and that are capable of adhering directly to the pellicle of the teeth. These bacteria are particularly used for treating or preventing dental caries and periodontal infection that are caused by cariogenic microorganism such as Streptococcus mutans and Streptococcus sobrinus.
  • Exogenous bacteria can also produce factors that inhibit the growth of the resident microflora in the mouth.
  • EP759469 (Institut des Produits Nestlé) described the use of a bacteriocin produced by Micrococcus varians for inhibiting the development of the oral pathogens S. sobrinus, S. sanguis, S. mutans and A. viscosus .
  • the application of bacteriocins is also one of the investigated strategies that have been set up to reduce tooth caries. These molecules have attracted interest as prospective anticaries agents and as factors important in modulating colonization of the oral cavity.
  • the present invention aims to provide the use of lactic bacteria that are exogenous to the oral microflora, which have been selected for their ability to adhere to the tooth surface and to produce a growth inhibition factor, for the preparation of a composition intended for reducing dental plaque and for treating or preventing root caries or other disease related to Actinomyces naeslundii in mammals.
  • the lactic bacteria may be selected from the group consisting of Streptococcus thermophilus, Lactococcus lactis subsp. lactis, and Lactococcus lactis subsp. lactis biovar diacetylactis and particularly from the group consisting of the strains CNCM I-1984, CNCM 1-1985, CNCM 1-1986, CNCM 1-1987.
  • Another object is to provide a composition for maintaining the health of the mouth by reducing the colonization of Actinomyces naeslundi , said composition comprises an exogenous lactic bacteria that has been selected for its ability to adhere to the tooth surface and to produce a growth inhibition factor.
  • Such a composition may contain at least 10 4 -10 9 cfu/g of lactic bacteria.
  • the invention also provides a method for the prevention or the treatment of Actinomyces naeslundi related infections, particularly dental plaque extent and root caries in a mammal, comprising the step of feeding a mammal a composition containing at least one lactic bacteria strain selected for its ability to adhere to the tooth surface and to produce a growth inhibition factor, said composition reduces the colonization of Actinomyces naeslundi.
  • the mouth defines the oral cavity of humans or animals such as pets, composed by the oral mucosa (gums, lips, cheeks, palate and floor of the mouth), the tongue and the teeth (including artificial structures).
  • inhibitor growth factor defines any extracellular substance produced by the adherent exogenous lactic bacteria that enables it to inhibit the growth of A. naeslundi.
  • the use of an exogenous lactic bacteria that has been selected for its ability to adhere to the tooth surface and to produce a growth inhibition factor, for the preparation of a composition intended for reducing dental plaque and for treating or preventing root caries or other disease related to Actinomyces naeslundi, is concerned.
  • the lactic bacteria may be selected from the group consisting of Streptococcus thermophilus, Lactococcus lactis subsp. lactis, and Lactococcus lactis subsp. lactis biovar diacetylactis and particularly from the group consisting of the strains Streptococcus thermophilus (NCC 1529) (CNCM 1-1984), Streptococcus thermophilus (NCC 1561) (CNCM I-1985), Lactococcus. lactis subsp. lactis (NCC 2211) (CNCM I-1986), Lactococcus. lactis subsp. lactis biovar dioacetylactis (NCC 2225) (CNCM 1-1987).
  • the lactic bacteria are preferably of dairy origin (i.e. originating from milk or cheese, for example).
  • the lactic bacteria according to the invention is “low acidifying”, which means that it is less acidifying than pathogenic strains. Accordingly, it can contribute to a pH in the oral cavity of about 5.5-7.
  • strains have been selected among lactic bacteria strains for their capacity of adherence to the pellicle of the teeth, their optimal growth temperature is about 37° C., which is the temperature in the oral cavity. They are also capable of producing a growth inhibition factor, which combined to their adhesion properties allow them to significantly decrease the colonization extent of A. naeslundii genospecies 1 and 2.
  • At least one lactic bacteria strain in combination with a bacteriocin, for example.
  • the lactic bacteria strains may be included in a food, pet food, cosmetic or pharmaceutical composition, for example. Accordingly, these compositions are preferably toothpaste, mouth rinse, gum, spray, beverage, candies, infant formula, ice cream, frozen dessert, sweet salad dressing, milk preparations, cheese, quark, yogurt, acidified milk, coffee cream or whipped cream, for example.
  • the exogenous lactic bacteria may be used in an amount of at least 10 4 -10 9 cfu/g of lactic bacteria.
  • Fermentation patterns 49 simple sugars were tested with the api 50 CH bioMerieux strip test (bioMérieux SA, 69280 Marcy-l'Etoile, France) and the results are given in Table 1. TABLE 1 Sugar fermentation of i L. lactis CNCM I-1987 (A), L. lactis CNCM I-1986 (B), S. thermophilus CNCM I-1984 (C), S. thermophilus CNCM I-1985 (D).
  • strains Sreptococcus thermophilus (NCC 1529), Sreptococcus thermophilus (NCC 1561), Lactococcus. lactis subsp. lactis (NCC 2211), Lactococcus. lactis subsp. lactis biovar dioacetylactis (NCC 2225) were deposited under the Budapest Treaty, at the Collection Nationale de Culture de Microorganismes (CNCM 1-1984, CNCM I-1985, CNCM I-1986 and CNCM I-1987 respectively), 25 rue du dondel Roux, 75724 Paris, France, on March 3 rd , 1998.
  • the second main object of the present invention relates to a composition for maintaining the health of the mouth by reducing the colonization of A. naeslundii in mammals, said composition comprises an exogenous lactic bacteria, which has been selected for its ability to adhere to the tooth surface and to produce a growth inhibition factor.
  • compositions are particularly intended for the prophylaxis or the treatment of dental plaque and infection related to A. naeslundii disease such as root caries, for example.
  • the lactic bacteria strain according to the present invention is selected from the group consisting of Streptococcus thermophilus, Lactococcus lactis subsp. lactis, and Lactococcus lactis subsp. lactis biovar diacetylactis and preferably from the group consisting of the strains CNCM I-1984, CNCM 1-1985, CNCM I-1986 and CNCM I-1987.
  • Such a composition may contain at least 10 4 -10 9 cfu/g of lactic bacteria.
  • Synergistic compositions may also be prepared, adding at least one bacteriocin, which is active against Gram-positive oral bacteria.
  • the oral hygiene compositions may comprise 0.00001 to 50%, and preferably from 0.00001 to 15% of purified bacteriocin, by weight of the composition.
  • the bacteriocin is preferably variacin (EP 0 759 469).
  • an oil-soluble antioxidant may also be included. Suitable antioxidants include the tocopherols, butyl-hydroxyanisole (BHA), butyl-hydroxytoluene (BHT), and ascorbyl palmitate.
  • BHA butyl-hydroxyanisole
  • BHT butyl-hydroxytoluene
  • the oil soluble antioxidant is present in amounts of from 0.005% to 0.5%, preferably 0.005% to 0.01% by weight of the composition.
  • Suitable abrasives for use in dentifrice compositions of the present invention include calcium carbonate, calcium aluminosilicate, alumina, hydrates alumina, zinc orthophosphate, plastic particles, and silica, of which silica is the preferred abrasive.
  • compositions according to the invention will have a pH which is orally acceptable and within which the activity of the said lactic bacteria is not compromised.
  • the pH may be in the range 3.0-9.5, preferably in the range 3.5 to 6.5.
  • compositions may be prepared by conventional processes comprising admixing the ingredients together in the appropriate relative amounts and finally, and if necessary, adjusting the pH to desired value.
  • Actinomyces naeslundii genospecies 1 (formerly A. naeslundii ) and 2 (formerly A. viscosus ) are among the strongest plaque forming oral strains. They are commonly isolated at root caries sites, in particular in humans over 40 years, and they are believed to be the major etiological agent of this disease.
  • the invention also provides a method for the prevention or the treatment of Actinomyces naeslundi -related infections in mammals, particularly dental plaque extent and root caries, comprising the step of feeding the mammal a composition containing at least one lactic bacteria strain selected for its ability to adhere to the tooth surface and to produce a growth inhibition factor.
  • the amount to be administered may be of at least about 10 4 -10 9 cfu/g of lactic bacteria.
  • L. lactis NCC2211 The strains S. thermophilus NCC 1561 (CNCM 1-1985) and L. lactis subsp. lactis NCC2211 (CNCM I-1986) (hereinafter L. lactis NCC2211) were incorporated in vitro in a biofilm mimicking dental plaque in vitro.
  • Saliva pellicle formation cover synthetic hydroxyapatite discs of 10 mm diameter (HY-APATITE®, Euro-Crystals, Landgraaf, The Netherlands) with 800 ⁇ l of human saliva and incubate for 4 h at room temperature under shaking (1 disc/well in a 24 holes sterile Nunclon plate).
  • HY-APATITE® Euro-Crystals, Landgraaf, The Netherlands
  • Bacterial consortium preparation grow S. thermophilus NCC 1561 , L. lactis subsp. lactis NCC2211 , S. sobrinus OMZ176 , S. oralis OMZ607 , A. naeslundii OMZ745 , V. dispar OMZ493 and F. nucleatum OMZ596 overnight at 37° C. in anaerobiosis in FUM-glucose ( S. thermophilus NCC 1561 in FUM-lactose), adjust the OD 550 to 1 with FUM and pool 2 ml of each oral bacterial suspension with 2 ml of either S. thermophilus NCC1561 or L. lactis subsp. lactis NCC2211.
  • the control mixture contains the five oral strains only.
  • Biofilm formation and recovery the procedure is as described in Guggenheim et al., 1998, Validation of a new biofilm model. J.Dent.Res. 77, (Spec Iss A): 110 (Abstract #38).
  • S. thermophilus NCC1561 , S. thermophilus NCC 1536 and L. lactis NCC2211 were tested for growth antagonism against A. naeslundii OMZ745 and A. viscosus OMZ105 (target strains).
  • S. thermophilus NCC1561 and L. lactis NCC2211 could be incorporated and grown in the plaque-like biofllm on the S-HA discs, and their total CFU/disc after 40.5 h are given in the Table 4. TABLE 4 Level of incorporation of the two dairy strains in the biofilm (CFU/disc). The values are the mean of three experiments with their standard deviations.
  • S. thermophilus NCC1561 L. lactis NCC2211 Method of inoculation ( ⁇ 10 6 ) ( ⁇ 10 6 ) Together with the oral 4.08 +/ ⁇ 1.78 5.76 +/ ⁇ 3.64 strains Before the oral strains 5.03 +/ ⁇ 2.21 3.87 +/ ⁇ 4.01
  • S. thermophilus NCC 1561 and L. lactis NCC2211 could be incorporated in a biofilm mimicking dental plaque and were able to modulate the oral microflora, significantly reducing the number total of cfu, and more specifically, these strains were able to significantly decrease the colonization extent of A. naeslundii genospecies 2. In addition the strains could inhibit the growth of A. naeslundii genospecies 1 and 2 in co-cultures.
  • the study was carried out in 58 days. In order to perform the experiment during the day, the active period of the animals had to be advanced of 7 hours totally; this was done in three steps on day 16, 17 and 18 as further described in detail.
  • the cariogenic strains were associated on days 21 and 22, while association of the dairy strains started on day 23 and lasted until day 57.
  • the animals were fed the dairy strains as supplement in a yogurt base that was included in the normal diet, as explained in the section.
  • the rats teeth were swabbed at the end of the study, on day 58.
  • the circadian biorhythm was stepwise reversed between days 16 and 18 by advancing the active phase of the rats each day on three occasions by adjusting the automatic light controls.
  • the drinking water was supplemented with 2% glucose and 2% sucrose to support the implantation of the associated bacteria.
  • the litters were distributed among the 3 treatments, 1 animal per cage, in a programmed feeder machine and began to receive the test diet as indicated in the table 10.
  • the test diet consisted of 18 yogurt meals containing the test strains alternating with 18 meals of the modified diet 2000a previously described.
  • Bacterial strains The strains listed in the Table 8 were used. TABLE 8 Bacterial strains that were used in this study Strain Relevant properties Growth conditions S. thermophilus NCC1561 S-HA adherent Belliker; 42° C. S. thermophilus NCC1536 Non-adherent control Belliker; 42° C. L. lactis NCC2211 S-HA adherent M17-lactose; 37° C. A. viscosus OMZ105 Plaque forming, BHI; 37° C. S-HA adherent
  • the tested LAB strains were associated daily (since contained in the yogurt base meal), starting on day 23. 2 frozen vials, each containing 2 ⁇ 10 11 viable cells of the test strain, were mixed in 200 ml of yogurt in order to have at least 10 9 CFU/ml. S. thermophilus NCC1536, a non S-HA adhering strain, was used as a negative control.
  • yogurt and diet 2000a meals of 1 ml and 400 mg respectively, were offered alternatively 18 times per day at 20-min intervals (Table 10). Therefore, each animal received in total 18 ml of yogurt and 7.2 g of powdered diet.
  • strains CNCM 1-1985 and CNCM-1986 are able to modulate the oral microbial ecology, significantly decreasing the colonization extent of A. naeslundii genospecies 2, with which the rats had been infected.
  • thermophilus NCC1561 and S. thermophilus NCC1536 were grown overnight in 1 l of Belliker at 42° C.
  • the procedure described in Busscher et al. (1997) Appl. Environ. Microbiol. 63, 3810-3817, (Busscher et al., 1997)was used.
  • the crude biosurfactant suspension was first analyzed by SDS-PAGE and then submitted to surface tension measurements.
  • SDS-PAGE was carried out with a precast 12.5% ExcelGel (Amersham Pharmacia Biotech). Silver staining was performed with the Plusone Silver Staining Kit (Amersham Pharmacia Biotech).
  • the surface tension of the biosurfactant suspensions was measured with a TVT1 Drop Volume Tensiometer (Lauda, Lauda-Königshofen, Germany), which is based on the drop volume principle. Briefly, the method consists in the exact determination of the volume of a suspension drop that detaches from a capillary. This volume (critical volume) is proportional to the surface tension ( ⁇ ), whose value is calculated with the relation:
  • ⁇ is the interfacial tension
  • V is the drop volume
  • G is the acceleration constant
  • ⁇ is the difference of the densities of both adjacent phases
  • r cap is the radius of the capillary
  • S. thermophilus NCC1561 and S. thermophilus NCC1536 cells are able to release substances with a surfactant activity. It is therefore possible that the biosurfactant produced by S. thermophilus NCC1561 makes the bacterium itself and the other oral strains established close to it detach from the tooth surface. By contrast, this action would not be displayed by S. thermophilus NCC 1536, since this strain does not adhere to the teeth.
  • Toothpaste is prepared by adding 10 5 cfu/ml of at least one of the lactic bacteria strain CNCM 1-1984, CNCM 1-1985, CNCM 1-1986, CNCM 1-1987 in a lyophilized form, to the following mixture containing: 1.65% Cetyl pyridinium chloride, 33.0% Sorbitol (70% soln), 25.0% Glycerin, 2.0% Sodium carboxymethyl cellulose, 0.25% Sodium fluoride, 26.3% Silica (RP 93), 8.1% Thickening Silica (Sident 22), 0.5% Sodium saccharine, 3.2% Poloxamer (Pluronic F 108).
  • This toothpaste is intended for the prophylaxis or the treatment of root caries, dental plaque and other infections induced by A. naeslundii species.
  • 5 l MRS culture medium are sterilized for 15 min at 121° C. and then inoculated with 5% by volume of an active culture of at least one of the S. thermophilus strain CNCM 1-1984, CNCM 1-1985 containing approximately 10 9 cfu/ml. After incubation for 8 h at 41° C., a starter containing 4.5.10 8 cfu/ml is obtained.
  • the yogurt obtained has a good firm and smooth texture and is intended for the health of the mouth.
  • a chewing gum for preventing or treating root caries, dental plaque or other A. naeslundii -related diseases can be prepared adding an active culture of at least one of the S. thermophilus strain CNCM 1-1984, CNCM 1-1985 so that it contains approximately 10 4 to 10 9 cfu/g, to the following typical ingredients: 67.5% Xylitol, 20% Gum base, 5% Calcium carbonate, 3% Glycerin, 2% Pluronic F127, 1% Cellulose gum, 0.5% Balast compounds and 1% Flavor.
  • a pet food for mouth health is obtained by preparing a feed mixture made up of corn, corn gluten chicken and fish meal, salts, vitamins and minerals.
  • the feed mixture is fed into a preconditioner and moistened.
  • the moistened feed leaving the preconditioner is then fed into an extruder-cooker and gelatinized.
  • the gelatinized matrix leaving the extruder is forced through a die and extruded.
  • the extrudate is cut into pieces suitable for feeding to dogs, dried at about 110° C. for about 20 minutes and cooled to form pellets that have a water activity of about 0.6.
  • the pellets are sprayed with 3 coating mixtures.
  • Each coating mixture contains active culture of at least one of the S. thermophilus strains CNCM I-1984, CNCM I-1985 but one coating mixture uses hydrogenated soy fat as a coating substrate, one coating mixture uses water as a coating substrate and one coating mixture uses protein digest as a coating substrate.
  • the pellets contain approximately 10 4 to 10 9 cfu/g of said strains.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Husbandry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
US10/305,024 1998-08-12 2002-11-27 Treatment of actinomyces naeslundii-related diseases with exogenous lactic bacteria strains Abandoned US20030170184A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/995,891 US7491386B2 (en) 1998-08-12 2004-11-23 Treatment of actinomyces naeslundii-related diseases with exogenous lactic bacteria strains

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00201948A EP1159951A1 (en) 2000-06-02 2000-06-02 Use of exogenous lactic bacteria strain against Actinomyces naeslundii-related diseases
EP00201948.7 2000-06-02
PCT/EP2001/006268 WO2001091711A1 (en) 2000-06-02 2001-05-30 Use of exogenous lactic bacteria strain against actinomyces naeslundii related diseases

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US09/779,596 Continuation US6942849B2 (en) 1998-08-12 2001-02-09 Incorporation of exogenous lactic bacteria into the oral microflora
PCT/EP2001/006268 Continuation WO2001091711A1 (en) 1998-08-12 2001-05-30 Use of exogenous lactic bacteria strain against actinomyces naeslundii related diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/995,891 Continuation US7491386B2 (en) 1998-08-12 2004-11-23 Treatment of actinomyces naeslundii-related diseases with exogenous lactic bacteria strains

Publications (1)

Publication Number Publication Date
US20030170184A1 true US20030170184A1 (en) 2003-09-11

Family

ID=8171588

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/305,024 Abandoned US20030170184A1 (en) 1998-08-12 2002-11-27 Treatment of actinomyces naeslundii-related diseases with exogenous lactic bacteria strains
US10/995,891 Expired - Fee Related US7491386B2 (en) 1998-08-12 2004-11-23 Treatment of actinomyces naeslundii-related diseases with exogenous lactic bacteria strains

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/995,891 Expired - Fee Related US7491386B2 (en) 1998-08-12 2004-11-23 Treatment of actinomyces naeslundii-related diseases with exogenous lactic bacteria strains

Country Status (25)

Country Link
US (2) US20030170184A1 (enrdf_load_stackoverflow)
EP (2) EP1159951A1 (enrdf_load_stackoverflow)
JP (1) JP2003534362A (enrdf_load_stackoverflow)
KR (1) KR20030031490A (enrdf_load_stackoverflow)
CN (1) CN1279890C (enrdf_load_stackoverflow)
AR (1) AR028672A1 (enrdf_load_stackoverflow)
AT (1) ATE343932T1 (enrdf_load_stackoverflow)
AU (2) AU2001272449B2 (enrdf_load_stackoverflow)
BR (1) BR0111371A (enrdf_load_stackoverflow)
CA (1) CA2410591A1 (enrdf_load_stackoverflow)
DE (1) DE60124255T2 (enrdf_load_stackoverflow)
ES (1) ES2275697T3 (enrdf_load_stackoverflow)
HU (1) HUP0301271A2 (enrdf_load_stackoverflow)
IL (1) IL153127A0 (enrdf_load_stackoverflow)
IN (1) IN2002CH01972A (enrdf_load_stackoverflow)
MX (2) MX243373B (enrdf_load_stackoverflow)
MY (1) MY142363A (enrdf_load_stackoverflow)
NZ (1) NZ522911A (enrdf_load_stackoverflow)
PE (1) PE20011328A1 (enrdf_load_stackoverflow)
PH (1) PH12001001365B1 (enrdf_load_stackoverflow)
PL (1) PL202576B1 (enrdf_load_stackoverflow)
PT (1) PT1296636E (enrdf_load_stackoverflow)
UY (1) UY26748A1 (enrdf_load_stackoverflow)
WO (1) WO2001091711A1 (enrdf_load_stackoverflow)
ZA (1) ZA200210308B (enrdf_load_stackoverflow)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070059295A1 (en) * 2005-06-01 2007-03-15 The Ohio State University Research Foundation Compositions and Methods for the Prevention and Removal of Biofilms on Inert and Biological Surfaces
WO2015048146A1 (en) * 2013-09-24 2015-04-02 The Regents Of The University Of Michigan Compositions and method for destabilizing, altering, and dispersing biofilms
US11464717B2 (en) 2017-02-10 2022-10-11 Evonik Operations Gmbh Oral care composition containing at least one biosurfactant and fluoride

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1287745A1 (en) 2001-08-24 2003-03-05 The Procter & Gamble Company Chewable compositions with probiotic agents
RU2011129693A (ru) * 2008-12-16 2013-01-27 Нестек С.А. Композиции и способы улучшения здоровья полости рта
JP2014506923A (ja) 2011-03-01 2014-03-20 クオラム イノベーションズ リミテッド ライアビリティ カンパニー 病原性バイオフィルムと関連した状態を治療するための物質および方法
CN104546941B (zh) * 2014-09-30 2019-01-08 深圳华大基因科技有限公司 内氏放线菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
BR112017026298A2 (pt) 2015-06-08 2018-09-11 Chr Hansen As produtos de bala de goma e de bala de marshmallow à base de glicerina com bactérias probióticas

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135739A (en) * 1983-02-15 1992-08-04 Kitasato Kenkyusho Non-cariogenic composition and drink
US5955602A (en) * 1994-08-19 1999-09-21 Nestec S.A. Branched lactose containing polysacharides and compositions containing them
US6036952A (en) * 1997-08-07 2000-03-14 Oh; Jong Suk Lactic acid bacteria inhibiting the formation of dental plaque in the mouth

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59220191A (ja) 1983-04-07 1984-12-11 Kitasato Inst:The 非う蝕性組成物および飲料
US4839281A (en) 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
CH671879A5 (enrdf_load_stackoverflow) 1987-02-26 1989-10-13 Nestle Sa
JPH0421633A (ja) 1990-05-17 1992-01-24 Saikon Medics:Kk 生体下口腔内有用微生物叢の維持管理法および維持管理組成物
FR2672494A1 (fr) 1991-02-13 1992-08-14 Madinier Isabelle Ferments prophylactiques favorisant la prevention de la carie dentaire.
DE4117782C2 (de) 1991-05-28 1997-07-17 Diagnostikforschung Inst Nanokristalline magnetische Eisenoxid-Partikel, Verfahren zu ihrer Herstellung sowie diagnostische und/oder therapeutische Mittel
JPH054927A (ja) 1991-06-28 1993-01-14 Aizo Matsushiro 乳酸菌含有組成物及びその製造方法
DK0768375T4 (da) 1992-07-06 2002-09-16 Nestle Sa Mælkesyrebakterier
GB9224598D0 (en) 1992-11-24 1993-01-13 Smithkline Beecham Plc Novel compositions
CH684773A5 (fr) 1992-12-28 1994-12-30 Nestle Sa Composition alimentaire anti-cariogène.
CO4560537A1 (es) 1992-12-28 1998-02-10 Nestle Sa Composicion lactea y procedimiento de preparacion
US5368845A (en) 1993-01-07 1994-11-29 Colgate Palmolive Company Oral composition
US5358858A (en) 1994-03-17 1994-10-25 National Science Council Process for preparing phycoerythrin from bangia atropurpurea and porphyra angusta
CA2199478A1 (en) * 1994-09-09 1996-03-14 Allan L. Delisle Bacteriophage-encoded enzymes for the treatment and prevention of dental caries and periodontal diseases
JP3101173B2 (ja) 1995-03-22 2000-10-23 雪印乳業株式会社 フローズンヨーグルトの製造法
DE69523294T2 (de) 1995-06-16 2002-04-18 Societe Des Produits Nestle S.A., Vevey Fluorierte Kasein-Mizellen
DK0759469T3 (da) 1995-08-07 2003-06-23 Nestle Sa Bakteriocin
JP3356599B2 (ja) 1995-09-22 2002-12-16 雪印乳業株式会社 低酸度型フローズンヨーグルトの製造法
CN1240372C (zh) * 1998-08-12 2006-02-08 雀巢制品公司 掺入口腔微生物区系的外源性乳酸菌
DE10034647C1 (de) * 2000-07-14 2002-04-04 3M Espe Ag Verfahren zur Durchführung einer Speichelanalyse

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135739A (en) * 1983-02-15 1992-08-04 Kitasato Kenkyusho Non-cariogenic composition and drink
US5955602A (en) * 1994-08-19 1999-09-21 Nestec S.A. Branched lactose containing polysacharides and compositions containing them
US6036952A (en) * 1997-08-07 2000-03-14 Oh; Jong Suk Lactic acid bacteria inhibiting the formation of dental plaque in the mouth

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070059295A1 (en) * 2005-06-01 2007-03-15 The Ohio State University Research Foundation Compositions and Methods for the Prevention and Removal of Biofilms on Inert and Biological Surfaces
US8038990B2 (en) 2005-06-01 2011-10-18 The Ohio State University Compositions and methods for the prevention and removal of biofilms on inert and biological surfaces
WO2015048146A1 (en) * 2013-09-24 2015-04-02 The Regents Of The University Of Michigan Compositions and method for destabilizing, altering, and dispersing biofilms
US10570401B2 (en) 2013-09-24 2020-02-25 The Regents Of The University Of Michigan Compositions and method for destabilizing, altering, and dispersing biofilms
US11464717B2 (en) 2017-02-10 2022-10-11 Evonik Operations Gmbh Oral care composition containing at least one biosurfactant and fluoride

Also Published As

Publication number Publication date
AU2001272449B2 (en) 2005-10-06
EP1159951A1 (en) 2001-12-05
DE60124255T2 (de) 2007-06-06
BR0111371A (pt) 2003-05-20
ES2275697T3 (es) 2007-06-16
WO2001091711A1 (en) 2001-12-06
PT1296636E (pt) 2007-02-28
MY142363A (en) 2010-11-30
EP1296636A1 (en) 2003-04-02
JP2003534362A (ja) 2003-11-18
ATE343932T1 (de) 2006-11-15
NZ522911A (en) 2003-08-29
CA2410591A1 (en) 2001-12-06
KR20030031490A (ko) 2003-04-21
IN2002CH01972A (enrdf_load_stackoverflow) 2005-02-11
EP1296636B1 (en) 2006-11-02
PH12001001365B1 (en) 2009-02-24
PE20011328A1 (es) 2002-01-23
ZA200210308B (en) 2004-03-19
PL360850A1 (en) 2004-09-20
US7491386B2 (en) 2009-02-17
MX243373B (es) 2007-01-19
PL202576B1 (pl) 2009-07-31
IL153127A0 (en) 2003-06-24
AU7244901A (en) 2001-12-11
HUP0301271A2 (hu) 2003-08-28
DE60124255D1 (de) 2006-12-14
MXPA01001038A (es) 2001-06-01
CN1279890C (zh) 2006-10-18
MXPA02011973A (es) 2003-04-22
AR028672A1 (es) 2003-05-21
CN1444469A (zh) 2003-09-24
US20050074416A1 (en) 2005-04-07
UY26748A1 (es) 2001-11-30

Similar Documents

Publication Publication Date Title
EP1104281B1 (en) Incorporation of exogenous lactic bacteria into the oral microflora
EP1002052A1 (en) Novel lactic acid bacteria
EP1296636B1 (en) USE OF EXOGENOUS LACTIC BACTERIA STRAIN AGAINST i ACTINOMYCES NAESLUNDII /i RELATED DISEASES
AU2001272449A1 (en) Use of exogenous lactic bacteria strain against actinomyces naeslundii related diseases

Legal Events

Date Code Title Description
AS Assignment

Owner name: NESTEC S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COMELLI, ELENA-MARIA;GUGGENHEIM, BERNHARD;NEESER, JEAN-RICHARD;AND OTHERS;REEL/FRAME:013898/0518;SIGNING DATES FROM 20030128 TO 20030204

AS Assignment

Owner name: NESTEC S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COMELLI, ELENA-MARIA;GUGGENHEIM, BERNHARD;NEESER, JEAN-RICHARD;AND OTHERS;REEL/FRAME:016027/0054;SIGNING DATES FROM 20030128 TO 20030204

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION